Thermo Fisher Scientific Bioproduction Brochures

31. Evolve Your Processes With Clinically Proven Cell Therapy Solutions 5/31/2023

    Explore a portfolio of products and systems that are well suited for both autologous and allogeneic applications.

32. CTS Dynacellect Magnetic Separation System 5/26/2023

    Explore the benefits of the CTS Dynacellect Magnetic Separation System from its use of a closed, automated environment to its rapid bead removal capabilities.

33. Bioproduction Regulatory Consulting Capabilities 12/20/2022

    Learn more about a service that provides regulatory support, validation guidance, internal consultations, and industry organization guidance while your company implements bioproduction solutions.

34. Evolve The Future Of Cell Therapy Manufacturing 10/17/2022

    Learn more about a closed, automated isolation and bead removal system for cell therapy manufacturing used to streamline and expedite your cell therapy development.

35. DynaDrive Single-Use Bioreactor (S.U.B.) 9/6/2022

    The Thermo Scientific DynaDrive Single-Use (S.U.B.) is the latest advancement based on our proven innovation, which offers better performance and accommodates larger volumes.

36. Process Liquid Preparation Services 5/11/2022

    We simplify pre-production workflows—for both upstream and downstream—by delivering fit-for-purpose process liquid and buffer preparation solutions that enable you to produce life-changing therapeutics and vaccines, faster.

37. Expand T Cells For Allogeneic Therapies With CTS OpTmizer Pro SFM 7/6/2021

    Gibco™ CTS™ OpTmizer™ Pro Serum-Free Medium (SFM) is a novel medium, developed for the growth and expansion of human T lymphocytes (e.g., CD4+, CD8+, polyclonal, or antigen-specific T cells) used in allogeneic cell therapies. CTS OpTmizer Pro SFM improves central memory phenotype and cell growth by shifting the cell’s metabolism. The result is a larger population of central memory cells in a shorter period of time. Body - First paragraph and features bullet points

38. ONE Lentiviral Vector Production System 2/5/2021

    Cost-effective lentiviral (LV) vector production is critical to meet commercial demand, and a smooth ramp-up to clinical production is essential. To address these needs, we have created a complete LV vector production system to help reduce costs and streamline your transition from research to clinical scale. The Gibco™ LV-MAX™ Lentiviral Production System is the first complete suspension production system.

39. Scaling Up With Gibco Media 2/5/2021

    From pioneering the use of serum, through our leadership in gene therapy and helping solve tomorrow’s challenges, Gibco™ media are known for innovation and quality. That expertise is especially valued by customers who are ready to scale up, or simply outsource, production of their own media formulations.